Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks

Page 7 of 10

4. Verona Pharma plc (NASDAQ:VRNA)

Number of Hedge Fund Holders: 25

Perceptive Advisors’ Stake: $13.8 million

Verona Pharma plc (NASDAQ:VRNA) is a United Kingdom-based biopharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. There are multiple factors that make Verona Pharma worth investing in. Firstly, as per the report of the third quarter of 2024, significant financial growth was seen as the net sales reported were $5.6 million, largely due to product sales of Ohtuvayre. Secondly, the company’s strategic projects like Ensifentrine hold future potential for investors. It is a first-in-class dual inhibitor of PDE3 and PDE4, targeting inflammation and bronchodilation in COPD patients. Moreover, Verona Pharma has partnered with Ritedose for the development and manufacturing of Ohtuvayre.

Page 7 of 10